Q4 2025 Immunology Perception Rankings
You can't "improve" your way to the top of immunology manufacturer rankings. You need to fundamentally flip the script from having critics to having advocates.
ZoomRx surveyed 50 US-based immunology HCPs in December 2025, evaluating 18 manufacturers across five dimensions: Innovation, Patient Centricity, Reputation, HCP Centricity, and Promotions.
Top 5 Manufacturer Rankings (Out of 100)
- AbbVie — 64 | Clinical rigor and a deep pipeline reinforce a reputation for scientific reliability
- Johnson & Johnson Innovative Medicine — 40 | "Human touch" engagement and accessible reps create strong partnership equity
- Sanofi — 27 | Dupixent's breakthrough success, paired with clear coverage pathways, anchors their position
- Eli Lilly — 27 | A rising innovator gaining ground through next-generation mechanisms and improved safety profiles — up from rank 8 in Q2 2025
- Amgen — 26 | Disciplined, evidence-based engagement and strong educational support drive credibility — up from rank 7 in Q2 2025
Three Critical Trends for Immunology in 2026
The rankings tell only part of the story. The full report uncovers three critical trends — from a counterintuitive top-of-mind paradox to a pipeline confidence gap that's already reshaping the competitive landscape — that explain why manufacturers rise, stall, or break through.
What's Inside the Full Report
- Perception scores for all 18 tracked manufacturers
- NPS data with promoter and detractor breakdown
- HCP verbatims on what drives loyalty and switching
- Current portfolio vs. pipeline confidence ratings
- Strategic imperatives for each Top 5 manufacturer heading into 2026
For a more granular view, you can explore these findings via ZoomRx Answers. Ask natural language questions to generate custom data views, listen to direct HCP voice clips, and review research artifacts in real-time.